EUVIMEDEUVIMED entdecken
Crossref

RSRC1 is a candidate progression-associated biomarker in cervical cancer linked to p53/CDK2-associated cell-cycle signaling

Yaqin Wu, Qian Li, Chenjing Zhu, Jing Luo, Biqing Zhu

European Journal of Pharmacology · 2026

DOI: 10.1016/j.ejphar.2026.179352 ↗

Kurz gefasst

Fachartikel in der Zeitschrift European Journal of Pharmacology, 2026. Verfasst von Yaqin Wu und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiation Oncology, Jiangsu Cancer Hospital, Jiangsu Institute of Cancer Research, Nanjing Medical University Affiliated Cancer Hospita…. Hauptthemen laut MEDLINE: Uterine Cervical Neoplasms, Cyclin-Dependent Kinase 2, Tumor Suppressor Protein p53, Signal Transduction. Die Arbeit nennt 36 Literaturangaben. Gefördert von: National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Cervical cancer (CC) remains a leading cause of cancer-related death among women, and the outlook for patients with advanced, recurrent or persistent disease is poor. Molecular markers that track disease progression and expose pharmacologically tractable vulnerabilities are therefore needed. GSE63514 and GSE138080 were used for exploratory candidate generation and cohort-specific disease-stage and discrimination analyses; random forest analysis was restricted to candidate prioritization. Prognostic relevance was assessed in TCGA-CESC (n = 304). Two independent siRNAs silenced RSRC1 in SiHa and CaSki cells, followed by viability, DNA synthesis, migration, cell-cycle and p53/CDK2 analyses. CDK2 overexpression, treatment with the p53 inhibitor pifithrin-α and a stable shRNA xenograft model evaluated pathway involvement and in vivo effects. RSRC1 expression increased across cervical disease stages. In GSE138080, RSRC1 discriminated cervical squamous cell carcinoma from non-carcinoma samples (area under the curve = 0.972, 95% confidence interval 0.925-1.000). High RSRC1 expression was associated with shorter overall survival (hazard ratio = 2.45, 95% confidence interval 1.55-3.87; P < 0.001) and remained independently associated after multivariable adjustment. In both cell lines, either siRNA reduced viability, DNA synthesis and migration, induced G2/M accumulation, increased p53 and decreased CDK2. CDK2 overexpression or pifithrin-α partially reversed these phenotypes. Stable RSRC1 depletion slowed xenograft growth, reduced Ki-67 and CDK2, and increased p53. RSRC1 is a candidate progression-associated biomarker that supports CC cell proliferation and migration. The findings support partial involvement of p53/CDK2-associated signaling, while independent clinical validation and direct characterization of RSRC1-regulated splicing remain necessary.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Uterine Cervical NeoplasmsCyclin-Dependent Kinase 2Tumor Suppressor Protein p53Signal TransductionBiomarkers, TumorCell CycleFemaleHumansAnimalsCell Line, TumorDisease ProgressionGene Expression Regulation, NeoplasticMiceCell MovementBenzothiazolesPrognosis

Stichwörter der Autor:innen

Cell cycleCervical cancerPre-mRNA splicingProgression-associated biomarkerRSRC1p53/CDK2 signaling

Substanzen

Cyclin-Dependent Kinase 2Tumor Suppressor Protein p53Biomarkers, TumorCDK2 protein, humanBenzothiazoles

Autor:innen und Institutionen

  • Department of Radiation Oncology, Jiangsu Cancer Hospital, Jiangsu Institute of Cancer Research, Nanjing Medical University Affiliated Cancer Hospital, Nanjing, China.
  • Department of Cardiothoracic Surgery, Jinling Hospital, Affiliated Hospital of Medical School, Nanjing University, Nanjing, China. Electronic address: luojing_2767983@163.com.
  • Department of Radiation Oncology, Jiangsu Cancer Hospital, Jiangsu Institute of Cancer Research, Nanjing Medical University Affiliated Cancer Hospital, Nanjing, China. Electronic address: zhubiqing81@outlook.com.

Förderung

  • National Natural Science Foundation of China

Zitieren

APA

Wu, Y., Li, Q., Zhu, C., Luo, J., & Zhu, B. (2026). RSRC1 is a candidate progression-associated biomarker in cervical cancer linked to p53/CDK2-associated cell-cycle signaling. European Journal of Pharmacology. https://doi.org/10.1016/j.ejphar.2026.179352

Vancouver

Wu Y, Li Q, Zhu C, Luo J, Zhu B. RSRC1 is a candidate progression-associated biomarker in cervical cancer linked to p53/CDK2-associated cell-cycle signaling. European Journal of Pharmacology. 2026. doi:10.1016/j.ejphar.2026.179352

BibTeX
@article{Wu2026,
  author = {Wu, Yaqin and Li, Qian and Zhu, Chenjing and Luo, Jing and Zhu, Biqing},
  title = {RSRC1 is a candidate progression-associated biomarker in cervical cancer linked to p53/CDK2-associated cell-cycle signaling},
  journal = {European Journal of Pharmacology},
  year = {2026},
  doi = {10.1016/j.ejphar.2026.179352}
}
Kostenlos starten →